Next Article in Journal
The Sequencing-Based Mapping Method for Effectively Cloning Plant Mutated Genes
Next Article in Special Issue
Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson’s Disease in C57BL/6 Mice
Previous Article in Journal
Degradation Products of Tryptophan in Cell Culture Media: Contribution to Color and Toxicity
Previous Article in Special Issue
The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know
Review

Bilirubin: A Promising Therapy for Parkinson’s Disease

1
Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy
2
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia
3
Molecular Biomedicine Ph.D. Program, University of Trieste, 34127 Trieste, Italy
4
Neurology Clinic, Department of Medical, Surgical, and Health Sciences, University of Trieste, 34139 Trieste, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Michael Ugrumov
Int. J. Mol. Sci. 2021, 22(12), 6223; https://doi.org/10.3390/ijms22126223
Received: 7 May 2021 / Revised: 28 May 2021 / Accepted: 30 May 2021 / Published: 9 June 2021
Following the increase in life expectancy, the prevalence of Parkinson’s disease (PD) as the most common movement disorder is expected to rise. Despite the incredibly huge efforts in research to find the definitive biomarker, to date, the diagnosis of PD still relies mainly upon clinical symptoms. A wide range of treatments is available for PD, mainly alleviating the clinical symptoms. However, none of these current therapies can stop or even slow down the disease evolution. Hence, disease-modifying treatment is still a paramount unmet medical need. On the other side, bilirubin and its enzymatic machinery and precursors have offered potential benefits by targeting multiple mechanisms in chronic diseases, including PD. Nevertheless, only limited discussions are available in the context of neurological conditions, particularly in PD. Therefore, in this review, we profoundly discuss this topic to understand bilirubin’s therapeutical potential in PD. View Full-Text
Keywords: bilirubin; yellow players; disease-modifying therapy; Parkinson’s disease bilirubin; yellow players; disease-modifying therapy; Parkinson’s disease
Show Figures

Figure 1

MDPI and ACS Style

Jayanti, S.; Moretti, R.; Tiribelli, C.; Gazzin, S. Bilirubin: A Promising Therapy for Parkinson’s Disease. Int. J. Mol. Sci. 2021, 22, 6223. https://doi.org/10.3390/ijms22126223

AMA Style

Jayanti S, Moretti R, Tiribelli C, Gazzin S. Bilirubin: A Promising Therapy for Parkinson’s Disease. International Journal of Molecular Sciences. 2021; 22(12):6223. https://doi.org/10.3390/ijms22126223

Chicago/Turabian Style

Jayanti, Sri, Rita Moretti, Claudio Tiribelli, and Silvia Gazzin. 2021. "Bilirubin: A Promising Therapy for Parkinson’s Disease" International Journal of Molecular Sciences 22, no. 12: 6223. https://doi.org/10.3390/ijms22126223

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop